203 related articles for article (PubMed ID: 22027573)
41. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
42. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
[TBL] [Abstract][Full Text] [Related]
43. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S
Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745
[TBL] [Abstract][Full Text] [Related]
45. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Wang SW; Pan SL; Huang YC; Guh JH; Chiang PC; Huang DY; Kuo SC; Lee KH; Teng CM
Mol Cancer Ther; 2008 Feb; 7(2):350-60. PubMed ID: 18281518
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
47. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Hawash MM; Kahraman DC; Eren F; Cetin Atalay R; Baytas SN
Eur J Med Chem; 2017 Mar; 129():12-26. PubMed ID: 28219046
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.
Kuo ZK; Lin MW; Lu IH; Yao HJ; Wu HC; Wang CC; Lin SH; Wu SY; Tong TS; Cheng YC; Yen JH; Ko CH; Chiou SJ; Pan IH; Tseng HW
BMC Complement Altern Med; 2016 Aug; 16():277. PubMed ID: 27502492
[TBL] [Abstract][Full Text] [Related]
50. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract][Full Text] [Related]
51. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
[TBL] [Abstract][Full Text] [Related]
52. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
53. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
54. Enhanced antitumor effects of novel intracellular delivery of an active form of menaquinone-4, menahydroquinone-4, into hepatocellular carcinoma.
Setoguchi S; Watase D; Matsunaga K; Matsubara M; Kubo Y; Kusuda M; Nagata-Akaho N; Enjoji M; Nakashima M; Takeshita M; Karube Y; Takata J
Cancer Prev Res (Phila); 2015 Feb; 8(2):129-38. PubMed ID: 25416411
[TBL] [Abstract][Full Text] [Related]
55. Sodium orthovanadate inhibits growth of human hepatocellular carcinoma cells in vitro and in an orthotopic model in vivo.
Wu Y; Ma Y; Xu Z; Wang D; Zhao B; Pan H; Wang J; Xu D; Zhao X; Pan S; Liu L; Dai W; Jiang H
Cancer Lett; 2014 Aug; 351(1):108-16. PubMed ID: 24858025
[TBL] [Abstract][Full Text] [Related]
56. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
[TBL] [Abstract][Full Text] [Related]
57. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.
Liu YM; Xia Y; Dai W; Han HY; Dong YX; Cai J; Zeng X; Luo FY; Yang T; Li YZ; Chen J; Guan J
BMC Cancer; 2014 Nov; 14():889. PubMed ID: 25429777
[TBL] [Abstract][Full Text] [Related]
58. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro.
García-Quiroz J; Cárdenas-Ochoa N; García-Becerra R; Morales-Guadarrama G; Méndez-Pérez EA; Santos-Cuevas C; Ramírez-Nava GJ; Segovia-Mendoza M; Prado-García H; Avila E; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2021 Nov; 214():105979. PubMed ID: 34438041
[TBL] [Abstract][Full Text] [Related]
59. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Deng M; Li L; Zhao J; Yuan S; Li W
Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
[TBL] [Abstract][Full Text] [Related]
60. Zoledronic acid inhibits growth of hepatocellular carcinoma cells in vitro and in vivo.
Liu Q; Tao YH; Bai RZ; Chang SJ; Hua D
Chin Med J (Engl); 2013; 126(8):1486-90. PubMed ID: 23595382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]